Rhythm Pharmaceuticals, Inc.

NasdaqGM:RYTM Rapport sur les actions

Capitalisation boursière : US$3.6b

Rhythm Pharmaceuticals Croissance future

Future contrôle des critères 5/6

Rhythm Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 66.7% et de 46.1% par an respectivement. Le BPA devrait croître de de 66.3% par an. Le rendement des capitaux propres devrait être -100.7% dans 3 ans.

Informations clés

66.7%

Taux de croissance des bénéfices

66.3%

Taux de croissance du BPA

Biotechs croissance des bénéfices28.4%
Taux de croissance des recettes46.1%
Rendement futur des capitaux propres-100.7%
Couverture par les analystes

Good

Dernière mise à jour08 Nov 2024

Mises à jour récentes de la croissance future

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 09
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Mar 03
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Recent updates

Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?

Sep 23
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Sep 22

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Aug 29

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

Jun 12

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 09
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

May 05
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Mar 03
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Rhythm Pharmaceuticals: Action Too Specific

Feb 23

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Jan 08
Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

Nov 03
We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Jul 23
We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Jun 17
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 05
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

Apr 01
Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

Dec 15
An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully

Oct 24
We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully

Rhythm Pharmaceuticals: Revisiting The Investment Thesis

Oct 10

Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours

Sep 14

Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS

Sep 06

Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts

Aug 08
Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts

Rhythm Pharmaceuticals Q2 2022 Earnings Preview

Aug 01

Rhythm Pharma gains as NICE recommends obesity drug

Jul 18

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:RYTM - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/2026312-642349
12/31/2025178-167-148-8811
12/31/2024124-266-271-14110
9/30/2024113-262-165-124N/A
6/30/2024102-261-169-128N/A
3/31/202492-274-182-140N/A
12/31/202377-185-142-136N/A
9/30/202362-186-146-141N/A
6/30/202344-182-164-159N/A
3/31/202334-181-161-156N/A
12/31/202224-181-174-173N/A
9/30/202217-181-173-180N/A
6/30/202213-176-166-173N/A
3/31/20225-166-160-166N/A
12/31/20213-70-139-146N/A
9/30/20211-62-135-135N/A
6/30/20210-60-122-122N/A
3/31/20210-56-120-119N/A
12/31/2020N/A-134-122-122N/A
9/30/2020N/A-132-125-125N/A
6/30/2020N/A-134-132-132N/A
3/31/2020N/A-146-130-127N/A
12/31/2019N/A-141-126-123N/A
9/30/2019N/A-133-115-112N/A
6/30/2019N/A-115-99-95N/A
3/31/2019N/A-87-83-82N/A
12/31/2018N/A-74-63-62N/A
9/30/2018N/A-59-49-49N/A
6/30/2018N/A-53N/A-40N/A
3/31/2018N/A-47N/A-34N/A
12/31/2017N/A-38N/A-29N/A
9/30/2017N/A-36N/A-28N/A
6/30/2017N/A-32N/A-24N/A
3/31/2017N/A-30N/A-24N/A
12/31/2016N/A-29N/A-23N/A
9/30/2016N/A-27N/A-21N/A
6/30/2016N/A-23N/A-18N/A
3/31/2016N/A-17N/A-13N/A
12/31/2015N/A-12N/A-7N/A
9/30/2015N/A-6N/A-4N/A
6/30/2015N/A-3N/A-4N/A
3/31/2015N/A-5N/A-6N/A
12/31/2014N/A-6N/A-8N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: RYTM devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.6% ).

Bénéfices vs marché: RYTM devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: RYTM devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de RYTM ( 46.1% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de RYTM ( 46.1% par an) devrait croître plus rapidement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: RYTM devrait être non rentable dans 3 ans.


Découvrir les entreprises en croissance